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Background: The number of knee arthroplasties and the prevalence of obesity are increasing exponen-
tially. To date there have been no published reviews on utilization rates of knee arthroplasty in OECD
countries.
Methods: We analysed economic, medical and population data relating to knee arthroplasty surgeries
performed in OECD countries. Gross domestic product (GDP), health expenditures, obesity prevalence,
knee arthroplasty utilization rates and growth in knee arthroplasty rates per 100,000 population were
assessed for total population, for patients aged 65 years and over, and patients aged 64 years and
younger.
Results: Obesity prevalence and utilization of knee arthroplasty have increased signiﬁcantly in the past.
The mean utilization rate of knee arthroplasty was 150 (22e235) cases per 100,000 total population in
2011. The strongest annual increase (7%) occurred in patients 64 years and under. Differences between
individual countries can be explained by economic and medical patterns, with countries with higher
medical expenditures and obesity prevalence having signiﬁcantly higher utilization rates. Countries with
lower utilization rates have signiﬁcantly higher growth in utilization rates. The future demand for knee
prostheses will increase x-fold by 2030, with exact rates dependant upon economic, social and medical
factors.
Conclusion: We observed a 10-fold variation in the utilization of knee arthroplasty among OECD coun-
tries. A signiﬁcant and strong correlation of GDP, health expenditures and obesity prevalence with uti-
lization of knee arthroplasty was found. Patients aged 64 years and younger show a two-fold higher
growth rate in knee arthroplasty compared to the older population. This trend could result in a four-fold
demand for knee arthroplasty in OECD countries by 2030.
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
In 2012 osteoarthritis (OA) affected 27% of the population in
industrialised countries aged over 45 years and this rate will in-
crease by 11% by 2032, when an additional 26,000 individuals per 1
million population will be affected. Among these patients, the
highest incidence of OA is found in the knee joint, which is affected
twice as often as the hip joint1. Although there are patients withto: C. Pabinger, Medical
ustria. Tel: 43-316-908204-0;
inger), harald@lothaller.net
ternational. Published by Elsevier Lasymptomatic arthritis, the need for knee arthroplasty will grow
exponentially2. Obesity is a major factor for the increasing demand
for knee arthroplasty3.
Knee arthroplasty is a validated treatment method4. Neverthe-
less, some knee implants are associated with remarkably inferior
long-term results and a systematic publication bias from its de-
velopers regarding implant quality has been found5,6. Furthermore,
it is of interest to assess how many implants are used annually in
different OECD countries.
A large variation of implantation rates for hip arthroplasty that
relate to economic and social differences across various countries
has been the subject of previous research, where a strong increase
in utilization rates in the population aged 64 years and under was
found7.td. All rights reserved.
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for knee arthroplasty. Accordingly, the goal of this study is to
analyse historical and epidemiological trends in knee arthroplasty
utilization across countries within the OECD health statistics
framework. Thereby, we focus on three speciﬁc questions:
a) What is the utilization rate of knee arthroplasty in OECD
countries and does it depend on age, obesity prevalence and
economic parameters?
b) How has the utilization rate in relation to the population rate
changed over time?
c) Which trends can be derived to predict the future use of knee
arthroplasty?Material and methods
Origin of data
We retrieved economic and medical data on knee arthroplasty
performed in OECD countries from 1990 to 2011 from the OECD
Health Data 2013 database8. As the majority of countries ﬁrst began
reporting data after 2005, we focused on the time period between
2005 and 2011 (or the latest available). We retrieved the following
variables for knee arthroplasty which is internationally identiﬁed
by ICD-9-CM code 81.54 (total knee replacement) from the OECD
statistics database: Inpatient cases per 100,000 population and
total procedures per 10,000 population (both variables also for
patients aged 65 years and over), total population and population
aged 65 years and over, annual gross domestic product (GDP) per
capita, annual healthcare expenditures per capita, the percentages
of obese population measured and the percentages of obese pop-
ulation self reported.Validation
Data validation was performed by comparing economic and
population data reported in multiple OECD databases. This data
was found to be similar across databases. No differences exceeding
5% were found between inpatient cases and total procedures
(including inpatient and outpatient cases). For Australia, only total
procedures per 100,000 population were reported. Body weight
data was retrieved from the ﬁrst measurements in 1980e2013.
Furthermore, OECD data were compared with register data, where
available. These differences did not exceed 5%9.Utilization rate
We emphasize, that our use of the term “utilization rate” is to be
distinguished from the term “incidence”. In calculating incidence, a
rate is derived by dividing the total number of a subgroup (e.g.,
“patients aged 65 years and over”) by “total population”. This
measure can, however, be misleading when the incidence of a
procedure (arthroplasty) is age-related i.e., it is more common in
one subgroup (“patients aged 65 years and over”) than in others
(“patients aged 64 years and younger”). Since arthroplasty pre-
dominantly affects the elderly, it seems appropriate to use a “uti-
lization rate” in which the total number of a subgroup is divided by
the population of the respective subgroup (numerator and de-
nominator refer to the same subgroup). This distinction was pub-
lished by an OECD and EFORT-EAR arthroplasty register study
group and is helpful when comparing values for different age
groups7.CAGR e compound annual growth rate
In order to compare growth rates across countries and over time
we calculated the CAGR, which illustrates the mean annual growth
rate in percentage points7.
Age groups
Patients were clustered into two age groups e “patients aged 65
years and over” and “patients aged 64 years and younger”.
Numbers and rates per 100,000 population in “patients aged 64
years and younger” were calculated as the total number of knee
arthroplasties minus the number of implants in patients aged 65
years and older.
Obesity
We adopted the deﬁnition of obesity from the World Health
Organization (WHO), which is based on the body mass index (BMI)
e a simple measure to evaluate the individual relation of height to
weight (kg/m2). Populations with a BMI equal to or above 25 are
classiﬁed as overweight and those with a BMI above 30 are deemed
obese. For most countries, overweight and obesity rates are self-
reported through estimates of height and weight from
population-based health interview surveys. However, around one-
third of OECD countries derive their estimates from health exami-
nations. These differences limit data comparability. Estimates from
health examinations are generally higher and more reliable than
those from health interviews. The following countries in our anal-
ysis usemeasured data: Australia, Canada, Chile, the Czech Republic,
Finland, Ireland, Japan, Korea, Luxembourg, Mexico, New Zealand,
the Slovak Republic, the United Kingdom and the United States10.
Statistics and correlations
APearson correlation of the followingmedical and economic data
was performed in order to identify dependencies between the
following variables: Incidence, population, CAGR (population),
number of implants, CAGR (implants), health expenditures, CAGR
(health expenditures), GDP, CAGR (GDP), obesity on a single year
basis from1980 to 2013, (CAGRof obesity in5 year intervals). Pearson
correlation is a measure of linear correlations between two variables
X and Y, giving a value betweenþ1 and1 inclusive, where 1 is total
positive correlation, 0 is no correlation, and 1 is total negative
correlation. A coefﬁcient higher than 0.5 will be interpreted as a
strong correlation andhigher than0.75 as avery strong correlation in
this context. The level of signiﬁcance is set at 5 percent.
Prediction model
For prediction of future number of implants, we applied a con-
stant growth rate in implants by projecting the individual CAGRs of
the respective countries from Table I (period 2005e2015) into the
future. This method underestimates countries with fast rising
economies and overestimates countries with future shrinking
economies. Nevertheless,we consider this approach to be reasonable
as it is based on current data without depending on predictions of
other future indicators concerning medical or economic situations.
Results
Origin of data
The OECD health statistics database contains utilization data
relating to knee arthroplasty for 28 countries. Only Finland has
Table I
Total utilization rate of knee arthroplasty per 100,000 population from 2005 to 2011
Inpatient cases per 100,000 total population Population in 2011 [million]
(CAGR 2005e2011)
Total number of implants
in 2011 (CAGR 2005e2011)
Health expenditure per
capita 2011 [$]
(CAGR 2005e2011)
GDP per capita 2011 [$]
(CAGR 2005e2011)
Share of obese
population
2011 or latest
2005 2006 2007 2008 2009 2010 2011
Australia 130 135 144 147 158 169 178 22.3 (1.7) 39,774 (7.0) 3,997 (4.8) 43,208 (3.6) 28
Austria 160 169 181 187 196 210 218 8.4 (0.4) 18,388 (5.8) 4,663 (4.9) 42,978 (4.2) 12
Belgium 143 150 156 166 174 178 184 11.0 (0.9) 20,332 (5.2) 4,227 (5.3) 40,093 (3.7) 14
Canada 125 136 138 142 144 148 159 34.5 (1.1) 54,825 (5.2) 4,503 (4.5) 41,163 (2.2) 25
Denmark 113 123 143 143 168 175 165 5.6 (0.5) 9,198 (6.8) 4,545 (5.8) 41,843 (3.9) 13
Finland 172 189 173 188 184 192 193 5.4 (0.4) 10,380 (2.4) 3,455 (4.9) 38,618 (3.9) 20
France 98 102 110 115 120 124 133 63.2 (0.5) 86,345 (5.7) 4,192 (4.4) 36,391 (3.5) 14
Germany 164 173 188 199 206 206 206 81.8 (0.1) 168,533 (3.7) 4,610 (5.4) 40,990 (4.7) 15
Hungary 48 48 41 45 41 42 59 10.0 (0.2) 5,890 (3.5) 1,800 (3.9) 22,413 (4.7) 29
Ireland 41 40 41 39 37 40 40 4.6 (1.6) 1,842 (1.2) 3,742 (4.1) 42,943 (1.7) 23
Israel 36 36 39 39 40 47 45 7.8 (1.9) 3,471 (5.6) 2,201 (3.1) 30,170 (3.8) 16
Italy 78 85 92 96 96 100 101 60.0 (0.4) 59,714 (4.8) 3,202 (4.2) 33,860 (3.0) 10
Korea 43z 55 79 84 97 108 111z 49.8 (0.6) 62,082 (20.2) 2,155 (8.9) 29,035 (4.1) 4
Luxembourg 157 156 165 164 157 152 163 0.5 (1.8) 795 (2.2) 4,661 (1.9) 88,668 (4.5) 24
Netherlands 84 96 105 109 112 118 126z 16.7 (0.4) 21,024 (7.4) 5,219 (5.3) 43,150 (3.5) 11
New Zealand 86 85 93 88 91 88 92 4.4 (1.1) 4,028 (2.1) 3,172 (6.9) 31,616 (3.7) 28
Poland 6 8 9 13 15 17 22 38.5 (0.2) 8,478 (25.6) 1,494 (9.7) 21,748 (7.9) 16
Portugal 24 48 46 54 62 80z 93z 10.6 (0.1) 10,520 (26.7) 2,642 (2.9) 25,672 (3.1) 15
Slovenia 40 49 57 75 86 81 110 2.1 (0.4) 2,262 (19.1) 2,556 (4.2) 28,156 (3.1) 18
Spain 85 88 92 97 98 101 105 46.2 (1.0) 48,885 (4.8) 2,998 (4.8) 32,156 (2.7) 17
Sweden 93 102 100 108 125 129 124 9.4 (0.8) 11,694 (5.7) 3,964 (5.0) 41,761 (4.2) 11
Switzerland 141 150 173 176 186 199 205 7.9 (1.0) 16,241 (7.5) 5,671 (5.9) 51,582 (5.9) 10
United Kingdom 111 118 131 134 132 134 140 63.3 (1.1) 88,379 (4.7) 3,212 (2.9) 35,091 (0.9) 25
United States 185 175 172 201 213 226 235z 311.6 (0.9) 733,447 (5.0) 8,483 (3.9) 49,782 (2.0) 36
Incidence* 114 115 119 131 137 144 150 TOTAL 875.5 (0.8) 1,486,527 (5.5) MEAN 3,807 (4.9) 38,879 (3.7) 18
Mean utilization ratey 114 115 119 131 137 144 150 SD 1,480 13,234 8
MEAN ¼ arithmetic mean; SD ¼ standard deviation.
Comments:
* Implants/100,000 total population.
y Implants/100,000 total population all ages.
z Rates calculated according to CAGR of implants of previous years.
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Table II
Utilization rate of patients aged 65 years and over per 100,000 total population from 2005 to 2011
Inpatient cases aged 65 years old and over per 100,000 total population Population [million] and share [%]
aged 65 and over in 2011
(CAGR 2005e2011)
Total number of implants in 2012
(CAGR 2005e2012)
Mean utilization ratey
2005 2006 2007 2008 2009 2010 2011
Australia 102 105 111 112 119 125 129 3.1 13.8% (2.8) 28,819 (5.8) 933
Austria 100 103 108 109 113 119 124 1.5 17.7% (1.9) 10,424 (4.0) 700
Belgium 84 87 92 98 102 104 108 1.9 17.2% (0.9) 11,932 (5.2) 627
Canada 96 102 102 104 104 105 110 5.0 14.5% (2.8) 37,932 (3.4) 761
Denmark 76 81 94 92 106 107 99 1.0 17.1% (2.5) 5,515 (5.0) 580
Finland 108 119 105 114 110 113 110 1.0 17.8% (2.3) 5,927 (0.8) 617
France 62 64 69 71 74 76 81 10.8 17.1% (1.1) 51,212 (5.1) 473
Germany 88 90 95 99 101 100 100 16.9 20.6% (1.3) 81,798 (2.0) 485
Hungary 30 30 25 28 25 25 35 1.7 16.8% (0.9) 3,486 (2.4) 208
Ireland 38 37 38 36 34 35 35 0.5 11.7% (2.5) 1,602 (0.2) 300
Israel 36 36 40 40 40 48 45 0.8 10.0% (2.1) 3,495 (5.8) 449
Italy 40 43 46 48 48 49 49 12.3 20.6% (1.2) 29,405 (3.8) 238
Korea 43z 55 79 82 91 98 98z 5.7 11.4% (4.4) 48,784 (15.4) 863
Luxembourg 107 107 113 112 107 104 112 0.1 13.9% (1.6) 581 (2.6) 804
Netherlands 60 67 73 74 75 77 80z 2.7 15.9% (2.4) 13,320 (5.3) 502
New Zealand 72 70 75 70 71 67 69 0.6 13.3% (2.8) 3,039 (0.3) 518
Poland 4 6 7 9 11 13 16 5.3 13.6% (0.7) 6,164 (26.2) 117
Portugal 14 28 27 31 35 41z 48z 2.0 18.9% (1.6) 4,801 (21.8) 241
Slovenia 26 31 36 47 52 49 67 0.3 16.7% (1.7) 1,375 (17.6) 402
Spain 51 54 56 59 59 60 61 8.0 17.2% (1.5) 28,167 (4.1) 354
Sweden 54 59 58 62 70 71 67 1.8 18.6% (2.0) 6,331 (4.4) 360
Switzerland 89 94 107 108 113 119 122 1.3 17.0% (2.2) 9,653 (6.5) 716
United Kingdom 70 74 83 84 82 83 85 10.5 16.5% (2.2) 53,792 (4.4) 514
United States 149 140 137 157 165 173 177z 41.4 13.28% (2.0) 550,671 (3.8) 1,331
Incidence* 82 81 83 91 95 98 101 TOTAL 135.8 (2.0) 998,223 (4.4) 735
Mean utilization ratey 634 625 637 688 708 728 735
Comments:
* Implants/100,000 total population.
y Implants/100,000 aged 65 years old and over.
z Rates calculated according to CAGR of implants of previous years.
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Table III
Utilization rate of patients aged 64 years and under per 100,000 total population from 2005 to 2011
Inpatient cases aged 64 years and younger per 100,000 total population Population [million] and share [%] aged 64
and younger in 2011
(CAGR 2005e2011)
Total number of implants in 2011
(CAGR 2005e2011)
Mean utilization ratey
2005 2006 2007 2008 2009 2010 2011
Australia 28 30 33 35 39 44 49 19.3 86.2% (1.5) 10,955 (9.1) 57
Austria 60 66 73 78 83 91 94 6.9 82.3% (0.1) 7,964 (7.2) 115
Belgium 59 63 64 68 72 74 76 9.1 82.8% (0.9) 8,400 (4.4) 92
Canada 29 34 36 38 40 43 49 29.5 85.5% (0.9) 16,893 (8.7) 57
Denmark 37 42 49 51 62 68 66 4.6 82.9% (0.1) 3,683 (8.5) 80
Finland 64 70 68 74 74 79 83 4.4 82.2% (0.1) 4,453 (4.2) 101
France 36 38 41 44 46 48 52 52.4 82.9% (0.4) 35,133 (5.6) 67
Germany 76 83 93 100 105 106 106 64.9 79.4% (0.5) 86,735 (4.8) 134
Hungary 18 18 16 17 16 17 24 8.3 83.2% (0.4) 2,404 (4.5) 29
Ireland 3 3 3 3 3 5 5 4.0 88.3% (1.5) 240 (8.9) 6
Israel 0 0 0 0 0 0 0 7.0 90.0% (1.9) N/A N/A N/A
Italy 38 42 46 48 48 51 52 47.7 79.4% (0.2) 30,309 (5.0) 64
Korea 0z 0 0 2 6 10 13z 44.1 88.6% (0.1) 13,298 N/A 30
Luxembourg 50 49 52 52 50 48 51 0.4 86.1% (1.9) 214 (1.1) 48
Netherlands 24 29 32 35 37 41 46z 14.1 84.2% (0.1) 7,704 (10.0) 55
New Zealand 14 15 18 18 20 21 23 3.8 86.7% (0.8) 989 (7.8) 26
Poland 2 2 2 4 4 4 6 33.3 86.4% (0.1) 2,314 (20.2) 7
Portugal 10 20 19 23 27 39z 45z 8.6 81.1% (0.2) 5,719 (27.0) 67
Slovenia 14 18 21 28 34 32 43 1.7 83.3% (0.2) 887 (18.5) 52
Spain 34 34 36 38 39 41 44 38.2 82.8% (0.9) 20,718 (5.0) 54
Sweden 39 43 42 46 55 58 57 7.7 81.4% (0.5) 5,363 (6.2) 70
Switzerland 52 56 66 68 73 80 83 6.6 83.0% (0.8) 6,588 (7.8) 100
United Kingdom 41 44 48 50 50 51 55 52.8 83.5% (0.9) 34,587 (4.4) 65
United States 36 35 35 44 48 53 58z 270.2 86.7% (0.7) 182,776 (8.0) 68
Incidence* 32 33 35 39 42 45 48 TOTAL 739.7 (0.6) 488,304 (7.1) 56
Mean utilization ratey 37 38 41 46 49 52 56
Comments:
* Implants/100,000 total population.
y Implants/100,000 aged 64 years and younger.
z Rates calculated according to CAGR of implants of previous years.
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Fig. 1. Increase in population and utilization of knee arthroplasty 2005e2011.
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(24) have reported valid data since 2005 (Table I). Four countries
(Chile, Czech Republik, Iceland and Norway) were excluded due to
poor data availability and Mexico was excluded due to inconsistent
data (>5% deviation among different databases).
Utilization rate
The utilization rate of knee arthroplasties varies between the
individual OECD countries by a factor of ten: Poland has the lowest
utilization rate of 22 per 100,000 total population and the US has
the highest rate of 235, with a mean rate of 150 in the year 2011
(Table I). In relation to patients aged 65 years and over (Table II), a
similar factor 10 variation can be found, although mean utilization
rate in this group is higher (735) compared with patients aged 64
years and under, where mean utilization rate is 56 (Table III).
Growth rates and age groups
The mean CAGR 2005e2011 for knee arthroplasty is 5.5% (range
1.2e26.7) for total population. The variation in growth rate among
the different OECD countries is considerable (Figs. 4 and 5): Korea,
Poland, Portugal and Slovenia show a growth rate of more than 13%
in every age group. Patients aged 64 years and younger show a
considerably higher annual growth rate of 7.1% (range 4.4e27) than
patients aged 65 years and older with a rate of 4.4% (range
0.3e26.2). This growth led to an absolute increase in total implants
of 38% from 2005 to 2011 (Fig. 1). The highest growth is found in
patients aged 64 years and under, where the number of implants
has grown by 63%, more than double the growth rate among pa-
tients aged 65 years old and over (29%). The highest dynamics and
the highest variation can be found in patients aged 64 years and
younger. The utilization rates of knee arthroplasty in OECD coun-
tries grew exponentially, and a plateau effect cannot be found in
either age group.
An increased utilization of knee implants of 29e63% between
2005 and 2011 cannot be explained by epidemiologic changes (i.e.,
overaging) as the total population in the respective OECD countriesTable IV
Signiﬁcant Pearson's correlation between medical and economic variables
Pearson's correlation r
(1) Utilization rate of knee arthroplasty 2011 and Health expenditures 2011 .768
(2) Utilization rate of knee arthroplasty 2011 and GDP 2011 .530
(3) Number of knee implants 2011 and Health expenditures 2011 .683
(4) Number of knee implants 2011 and Obesity each single year 1991e2006 .507e
(5) Number of knee implants 2011 and Obesity each single year 2007e2012 .458e
(6) CAGR Obesity 2005e2010 and Obesity each single year 1998e2006 .579egrew by only 5%, the population in patients aged 65 years and over
grew by 11%, and the population in patients aged 64 years and
under grew by 4% in the same time period.
Obesity
Obesity rates vary between 36.1% (USA) and 4.1% (Korea) in
2010. The availability of data post 2010 and pre 1990 is limited. The
median percentage of obese population in OECD countries grew
signiﬁcantly from 7.5% (range 5.8e14.66) in 1990 to 18.7% (range
4.1e36.1) in 2010. CAGR of median obesity is 5% from 1990 to 2010
and 3% from 2005 to 2011.
Correlations
An increase in obesity, GDP and health care expenditures was
found in all countries between 2005 and 2011 (Table I). These pa-
rameters correlate signiﬁcantly and strongly as follows (Table IV
and Fig. 3):
(1) The utilization rate of knee arthroplasty correlates with
healthcare expenditures.
(2) The utilization rate of knee arthroplasty correlates with GDP.
(3) The total number of implants in OECD countries correlates
with healthcare expenditures.
(4) The total number of implants in OECD countries correlates
very strongly with the annual obesity prevalence estimates
from 1991 to 2008.
(5) The total number of implants in OECD countries correlates
strongly with obesity annual obesity prevalence estimates
from 2007 to 2012.
(6) The CAGR of obesity from 2005 to 2010 correlates negatively
with annual obesity prevalence estimates from 1998 to 2006.
No signiﬁcant correlation was found between obesity and GDP
or healthcare expenditures.
Prediction model
A prediction model employing a constant growth rate based on
unchanged past CAGR values demonstrated an exponential growth
in knee arthroplasty utilization. Based on this assumption, an
exponential increase in the utilization of knee arthroplasty up to
the year 2030 can be shown (Fig. 2).
Discussion
Utilization rate
Utilization rates of knee arthroplasty differ between individual
OECD countries. However, the variation by a factor of 10 between
different OECD countries are lower than variations found in hip
arthroplasty utilization, where rates differ by a factor of 387. These
differences will reduce as the predicted higher growth rate ofP Countries excluded
<.001 None
<.008 None
<.001 None
.716 .006e.023 For 4e13 countries no obesity data available in single years
.601 .037e.063 For 4e14 countries no obesity data available in single years
.596 .041e.048 For 11e12 countries no obesity data available in single years
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Fig. 2. Scenario for the future use of knee arthroplasty.
C. Pabinger et al. / Osteoarthritis and Cartilage 23 (2015) 1664e16731670utilization in countries that currently have lower utilization rates
will lead to a homogenisation of rates across countries in the near
future.
Growth rates and age groups
The 63% increase in utilization of knee implants for patients
aged 64 years and younger from 2005 to 2011 must be considered
in the context of a 4% increase in population during the same time
period. The over proportional use of knee implants (þ38%) in the
last years is in contrast to a minor (23%) increase for hip implants in
the same time interval7. An explanation can be found in the higher
prevalence of OA of the knee (13.8%) as compared to the hip (5.8%)
and the rising incidence of knee OA and obesity1,11.
Obesity
Median obesity in OECD countries grew at 5% CAGR from 1990
to 2011, with countries that have a lower percentage of obesityChile 
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Fig. 3. Correlation between economic dashowing a signiﬁcantly higher growth rate than countries that
currently have high percentages of obesity in the population. While
the economic crisis is likely to have contributed to further growth
in obesity, steering effects, awareness-raising, healthcare, regula-
tory and ﬁscal measures have contributed to a slowing of obesity
rates in recent years12. Obesity prevalence from 1990 to 2008 is
correlated with the number of implants in 2011, whereby no bias in
economic data (GDP, health expenditures) was found. This in-
dicates that obesity is an inﬂuencing factor for knee arthroplasty e
a ﬁnding which is supported by other research3.
Correlations
(1) to (3): The variation in utilization rates for knee arthroplasty
between different OECD countries correlates signiﬁcantly and
strongly with variations in GDP and healthcare expenditures.
This was also found for hip arthroplasty7. This means that
ﬁnancial contributions to the national healthcare system result
in an increase in operative procedures and vice versa. Countries
with a higher GDP can afford a higher utilization of knee im-
plants. As a consequence of more implant usage, healthcare
expenditures and GDP rise. As we found no signiﬁcant correla-
tion between obesity prevalence and GDP or healthcare ex-
penditures, we consider that our results are not biased by the
assumption that countries with higher GDPs have a higher
obese prevalence.
(4) Obesity in early years (1991e2006) correlates very strongly
with the use of knee implants 5e20 years later. This underlines
that obesity is a major cause for late OA of the knee, a ﬁnding
which is supported by other studies3.
(5) A short-term effect whereby obesity leads to higher utili-
zation of knee implants within 1e5 years was also found,
although this correlation is not as strong as the long term effect.
Hence, it can be hypothesized that OA develops over a longer
time.
(6) We found a strong negative correlation between a countries'
absolute rate of obesity and its CAGR of obesity. Our interpre-
tation of these ﬁndings is that countries with higher proportions
of obese persons will experience lower increases in obesity ratesAustralia 
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Countries with lower obesity prevalence show more rapid in-
creases in obesity over time andwill have a higher percentage of
obese people in the future. It appears as though most countries
are approaching a generally high level of obesity and that
obesity prevalence among different countries is becoming
increasingly similar.
Future trends
The following ﬁve effects will lead to an excessive use of knee
implants and revisions in the future:
 As utilization rates of implants and economic power (GDP/
healthcare expenditures) correlate, a further increase in knee
implants utilization can be predicted in all countries with a
growing economy. The same association was found for hip
implants7.0,0 
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Fig. 5. Growth rates in knee arthro Some countries show a CAGR of over 10% in knee arthroplasty in
patients aged 64 and under (Australia, Denmark, Korea, Poland,
Portugal, Slovenia). These younger patients have a higher like-
lihood of undergoing revision surgery in the future than older
patients as the cumulated relative risk (CRR) for knee revision in
patients aged 64 and under is double that compared to patients
aged 65 years and over4. Consequently this will lead to an
exponential additional need for revisions of implants in the
current group of patients aged 64 years and under, resulting in
an increased utilization rate in older patients also.
 Obesity contributes to increased demand for knee arthroplasty.
Interestingly, BMI played the most substantial role in the
increased demand for total knee arthroplasty above that of total
hip arthroplasty, with younger individuals affected to a greater
degree3.
 Median life expectancy grew from 60 to 70 years worldwide
from 1990 to 2012 and will increase in the future13.
 As healthy life expectancy continues to increase, more elderly
people are likely to undergo operation, although there are some
ethnic and geographic differences14,15.
As Germany and the USA account for two thirds of all implants
used, both countries will inﬂuence the future use of knee and hip
implants to a great extent7. Nevertheless, the future implantation
rate for knee arthroplasty is not only a factor of medical necessity
and ﬁnancial power, but also driven by a variety of additional
factors:
 Incentive systems: The inﬂuence of different reimbursement
methodologies on utilization has been demonstrated in Ger-
many, where the number of surgical procedures, especially hip
and knee arthroplasty, rose signiﬁcantly following the imple-
mentation of the DRG-based hospital payment
system (Fig. 2)7,16.
 Budgetary constraints may necessitate regulation of arthro-
plasty rates in individual countries and reductions in growth
rates can occur in some countries, as found in Ireland for hip
arthroplasty7. Interestingly, the economic downturn in the USA
did not inﬂuence utilization rates for knee and hip athroplasty2.
The expansion of universal health insurance can help to reduce
disparities in access to elective surgery according to race/
ethnicity but not according to income15.
 As meta analyses show, a weight loss of only 5% reduces
disability signiﬁcantly and a weight reduction of 10% improvesC
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C. Pabinger et al. / Osteoarthritis and Cartilage 23 (2015) 1664e16731672function by 28%, which could contribute to a reduced need for
knee arthroplasty17,18.
Prediction model
We assumed a constant growth rate in total utilization of knee
implants in each OECD country with the current CAGR. Due to the
above-mentioned factors (economic growth, more implants in
younger patients, growing obesity and life expectancy) an expo-
nential 4-fold increase in the utilization of knee implants by 2030
can be predicted, with 5.7 million implants used then (Fig. 2). This
increase is comparable to utilization patterns in the USA, where a
similar increase for knee implants in the same period of time has
been reported by others19. These values are also comparable to
forecast increases in hip arthroplasty in Sweden by 2030 in accor-
dance with a prognostic model from the Swedish hip arthroplasty
register20. Another study also reported an overproportional use of
knee implants in patients who were 45e64 years of age, but the
rapid expansion of use of total knee replacements cannot be fully
explained by changes in population size and obesity prevalence
alone. Consequently, data suggest that other factors, including
expanding indications (more sports-related injuries, greater de-
mand by direct-to-consumer advertising) for total knee replace-
ment and shifting patterns of total knee replacement use among
those with OA, must be involved21.
Limitations: There are errors in reporting, incomplete reporting,
and data from private institutions of a magnitude less than <5% per
country missing. Countries with inconsistent data exceeding this
value were excluded.
We focussed on real historical data and our model assumes that
economic and social factors will remain unchanged in the future.
We are aware that there are currently too many variables to show a
conﬁdence band.
Conclusion: We observed a 10-fold variation in knee arthro-
plasty utilization between the different OECD countries. These
variations can be explained by different economic power and
medical conditions, with the correlation of higher implantation
rates in countries with higher prevalence of obesity being sig-
niﬁcant. The dynamics of medical (obesity, age), economical
(population, GDP, healthcare expenditures) and political (regu-
lation, reimbursement) factors could result in a fourfold increase
in knee arthroplasty utilization by 2030. This forecast could,
however, vary in accordance with changes in incentive systems,
budgetary constraints and health status (e.g., weight loss
recommendations).
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